Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Roche and Isis Pharmaceuticals have formed an alliance to develop treatments for Huntington’s disease based on Isis’ antisense oligonucleotide technology. Roche will pay Isis $30 million up front and could make license and milestone payments of $362 million. The partners will initially focus on an Isis drug candidate that blocks production of all forms of the huntingtin protein, which is responsible for the disease. The candidate was discovered with assistance from CHDI Foundation, a nonprofit devoted to developing Huntington’s therapies.
This article has been sent to the following recipient: